BMP2 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma line, designed for loss-of-function analysis of the BMP2 gene. This heterogeneous pool of edited cells, generated through targeted gene disruption, provides a robust model for dissecting BMP2-dependent signaling without the clonal selection bottlenecks of monoclonal lines. The polyclonal format retains population-level diversity, enabling studies that require physiological representation of genetic heterogeneity often observed in tumor biology.
The A2780 cell line was established from an untreated primary tumor of a patient with endometrioid adenocarcinoma, making it a clinically relevant model for ovarian cancer research. These cells are widely used to investigate mechanisms of chemoresistance, migration, and invasion, and they harbor signaling alterations common in high-grade serous ovarian carcinomas. Their epithelial origin and well-documented response to TGF-beta superfamily ligands render them particularly suitable for studying BMP2-mediated processes in a cancer context.
BMP2 encodes a secreted ligand of the TGF-beta superfamily that critically regulates bone formation, differentiation, and apoptosis. Mechanistically, BMP2 binds to type I (BMPR1A/BMPR1B) and type II (BMPR2) receptors, triggering phosphorylation of SMAD1/5/8. These activated SMADs complex with SMAD4 and translocate to the nucleus to transcriptionally modulate targets such as ID1, ID2, and RUNX2. The pathway is tightly controlled by antagonists like Noggin, Chordin, Gremlin, and Follistatin, and co-receptors like Endoglin. Upstream regulators, including RUNX2, MSX2, DLX5, retinoic acid, hedgehog signals, and inflammatory cytokines (TNF-alpha, IL-1beta), converge on BMP2 expression. Downstream, BMP2 influences genes encoding osteogenic markers (ALP, OCN, BSP, COL1A1) and matrix metalloproteinases (MMPs), linking it to tissue remodeling and cancer progression.
In A2780 cells, BMP2 signaling has been implicated in epithelial-mesenchymal transition and drug resistance, two hallmarks of ovarian cancer aggressiveness. Disruption of BMP2 in this knockout model allows direct interrogation of its role in autocrine and paracrine signaling loops that may drive malignant phenotypes. Researchers can compare wild-type and BMP2-null populations to ascertain the contribution of BMP2 to cell motility, invasion, and sensitivity to chemotherapeutics, while also exploring crosstalk with parallel TGF-beta/SMAD pathways. The polyclonal nature of these cells ensures that results are not skewed by clone-specific artifacts, closely mimicking the heterogeneity of clinical tumors.
This BMP2 knockout cell population is a powerful tool for a broad range of functional and pharmacological studies. Typical applications include Western blotting for phospho-SMAD1/5/8 to verify signaling abrogation, RT-qPCR quantification of ID1 and ID2 transcriptional changes, and Transwell migration assays to assess invasive potential. Cell viability (MTT) and apoptosis (Annexin V) assays can evaluate altered drug responses, while RNA-seq transcriptomics enables genome-wide discovery of BMP2-regulated networks. These cells are well-suited for screening BMP pathway inhibitors and for elucidating mechanisms of metastasis and chemoresistance in ovarian cancer. For further details or custom inquiries, please contact Ascent Research.
